PRME
Prime Medicine, Inc.
$3.78
-0.45 (-10.64%)
At close · Jul 10
Market Cap
$682.73M
Shares
180,617,451
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$4.63M
+55.3%
FY2025
Net Income
-$201.14M
-2.7%
FY2025
Operating Margin
-4498.06%
+2289.3pp
FY2025
Diluted EPS
-$1.35
+18.2%
FY2025
Operating Cash Flow
-$162.56M
-32.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| — | $4.63M | $2.98M | — | $0 | |
| $154.18M | $160.64M | $155.29M | $147.91M | $86.73M | |
| $56.47M | $52.35M | $50.16M | $43.39M | $29.82M | |
| $7.48M | $7.32M | $6.13M | $4.65M | $2.22M | |
| $210.65M | $212.98M | $205.45M | $204.79M | $116.54M | |
| -$206.61M | -$208.35M | -$202.47M | -$204.79M | -$116.54M | |
| — | -4498.06% | -6787.36% | — | — | |
| -$199.14M | -$201.03M | -$196.34M | -$200.14M | -$114.32M | |
| $3.99M | $4.15M | $3.52M | — | — | |
| $8.24M | $7.21M | $6.59M | $6.38M | -$6.23M | |
| — | $0 | $0 | -$279K | -$948K | |
| -$198.37M | -$201.14M | -$195.88M | -$198.13M | -$121.82M | |
| — | -4342.44% | -6566.61% | — | — | |
| -$198.37M | -$201.14M | -$195.88M | -$198.13M | -$142.01M | |
| -$198.36M | -$201.06M | -$195.87M | -$197.76M | -$122.18M | |
| USD/shares | — | -$1.35 | -$1.65 | -$2.18 | -$4.19 |
| USD/shares | — | -$1.35 | -$1.65 | -$2.18 | -$4.19 |
| shares | — | 148.76M | 118.6M | 90.97M | 33.89M |
| shares | — | 148.76M | 118.6M | 90.97M | 33.89M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Reportable Segment | $4,632,000 | $2,983,000 | $0 |